Abstract:Hepatitis C virus (HCV) is one of the major pathogens that lead to viral hepatitis. At present, Interferon treatment in combination with ribavirin is the first line clinical therapeutic approach. However, the responses are usually poor and the viral infection reoccurs. Therefore, exploring new antiviral agents and therapies is under urgent needs.The sequence and structure of the core coding region of HCV genome were analyzed through the two computer software, DNAMAN and RNA Structure. The cytosine 52 nt downstream of the AUG initiation triplet was identified as the optimal target cleavage site. Based on the flanking sequence of this assumed cleavage site, a guide sequence (GS) was designed and covalently linked to the 3 prime terminus of the M1 RNA, which is catalytic subunit of the RNase P derived from Escherichia coli using PCR. We named this new targeting ribozyme M1GS-HCV/C52 and it antiviral activities were analyzed in cultured cells.In the in vitro cleavage assay, M1GS-HCV/C52 ribozyme could effectively cleave the HCV target RNA into two fragments at the specific cleavage site. Moreover, comparing to the blank control, this engineered M1GS ribozyme could reduce the core protein expression of more than 80% in the HCV-infected host cell and lead to a 1500-fold reduction of HCV RNA copies in the culture supernatant. An another M1GS ribozyme, M1GS-HCV/C52*, which has the same guide sequence but does not contain a 24nt-long bridge sequence, did not exhibit apparent inhibition for the expression of HCV core gene and viral proliferation in our paralleled assay.We successfully constructed an M1GS ribozyme showing affective and specific cleavage of target viral RNA. Further results showed that the engineering ribozyme had notably antiviral activity in cultured cells, thus provided a new promising approach for clinical anti-HCV therapeutic strategy.

Two-unit ribozyme mediated cleavage against hepatitis B virus

Hammerhead Ribozymes Suppress HBV(adr) in HepG2 Cells

Intracellular Application of Two-Unit Ribozyme Gene Against Hepatitis B Virus

Effect of Ribozymes on Inhibiting Expression of HBV Mrna in HepG2 Cells

Design and activity assessment of HDV ribozymes to trans-cleave HCV RNA

Activity of Hdv Ribozymes to Trans-Cleave Hcv Rna

Preliminary Study on the Inhibition of HBeAg Expression in Cells by Ribozyme

In vitro self-cleavage activity of hepatitis delta virus ribozymes with different length and its significance

Study on the Cleavage Activity of U1 Small Nuclear RNA Chimeric Ribozyme Against HCV RNA in Vitro

Anti-viral activity of hairpin ribozyme directed against HBV core region in vitro

Inhibition of Dual-Target Ribozyme Against HBV on HBeAg in HHCC Cells

Inhibition of Hepatitis B Virus Gene Expression by Single and Dual Small Interfering RNA Treatment

Investigation on Activities of Hammerhead Ribozyme Embedded in Genomic RNA of Hepatitis Delta Virus

Determination of the in vitro antiviral activity of an engineered M1GS ribozyme that targets to the core gene of hepatitis C virus]

[Cleavage of HCV by HCV Specific Deoxyribozyme in Vitro].

The intracellular antiviral activities of a novel engineered M1GS ribozyme that targets to 5' untranslated region of hepatitis C virus genome

Invitro Cleavage of Hpv16 E6 and E7 Rna Fragments by Synthetic Ribozymes and Transcribed Ribozymes from Rna-Trimming Plasmids

The cleavage of PreC/C mRNA of HBV in vitro by a 10-23DNAzyme

In Vitro Enzymatic and Cell Culture-Based Assays for Measuring Activity of HBV Ribonuclease H Inhibitors

[Construction of the Expression Vectors of HDV Ribozymes and Their Intracellular Inhibiting Activity Against HCV RNA].

Effective Inhibition of Expression of Hepatitis B Virus Genes by DNAzymes.